Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00269516 · ClinicalTrials.gov registry record · Phase 3
SLV308 for Treatment of Patients With Early Parkinson's Disease
A Phase 3 study, sponsored by Solvay Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 468
- Enrollment target
NCT00269516 is a Phase 3 study that has completed, run by Solvay Pharmaceuticals. The registered enrollment target is 468 participants.
The verdict
NCT00269516, a Phase 3 study, has completed, sponsored by Solvay Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 468 participants
- Enrollment target
Study Summary
This study is a multicenter, randomized, double blind, parallel group study of 6 months' treatment with SLV308 administered as a monotherapy in patients with early stage PD. An open label safety extension to this study is planned as a separate protocol for patients who are willing and eligible to participate.
Interventions
- DRUG Placebo
- DRUG pardoprunox
- DRUG Pardoprunox
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 468 participants |
| Start Date | 2006-06 |
| Est. Completion | 2007-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00269516
The ClinicalTrials.gov registry entry for NCT00269516 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 468 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Solvay Pharmaceuticals, which has 35 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00269516 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00269516 about?
NCT00269516 is a clinical study titled "SLV308 for Treatment of Patients With Early Parkinson's Disease". This study is a multicenter, randomized, double blind, parallel group study of 6 months' treatment with SLV308 administered as a monotherapy in patients with early stage PD. An open label safety extension to this study is planned as a separate protocol for patients who are willing and eligible to pa...
What is the current status of trial NCT00269516?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 468 participants. The study started on 2006-06. Estimated completion is 2007-12.
What interventions are being tested in trial NCT00269516?
The interventions under investigation include: Placebo (DRUG), pardoprunox (DRUG), Pardoprunox (DRUG).
Who is sponsoring clinical trial NCT00269516?
This trial is sponsored by Solvay Pharmaceuticals, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.